Please assess the completion status of the following clinical trial:

Trial Title: CD34+ Stem Cell Infusion to Augment Graft Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for this protocol, patients must have the following:~1. Primary immunodeficiency (e.g. SCID, Wiskott-Aldrich and/or other more rare conditions and other bone marrow failure syndromes) with prior allogeneic stem cell transplant.~2. Waning donor chimerism or immune function that is inadequate to correct their disease or clinical condition, for which primary transplant was given, as determined by their attending physician.~3. Available primary donor.~4. Must not have other organ dysfunction deemed by the attending physician to preclude this procedure.~5. Age \< 35 years at time of transplant~6. One of the following must be true:~   * Patients must have evidence of persistent or recurrent immunodeficiency or thrombocytopenia.~-OR-~• Primary immunodeficiency disease with known potential to progress to malignant condition if untreated.~-OR-~• Debilitating secondary disease known to be a consequence of inadequate immune response to known agent or pathogen, uncontrollable by other available medical therapies (e.g. third patient described on page 5).~Exclusion Criteria:~1. Absence of an available original donor~2. Failure to sign consent form, or inability to undergo informed consent process~3. Pregnant or lactating female~4. Uncontrolled GVHD

- Gender: ALL
- Minimum Age: None
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- CD34+ selected stem cell infusion (Type: EXPERIMENTAL): An infusion of selected CD34+ stem cells will be given without any preparative regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).